Previous 10 | Next 10 |
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 PR Newswire Clinical data from dual combination COM701/nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints ...
Compugen Letter to Shareholders PR Newswire HOLON, Israel , Sept. 22, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, is pleased to issue the following l...
Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn. For further details see: Verve Therapeutics: Cathie Wood Adds To ARKK
Clinical-stage cancer immunotherapy company Compugen ( NASDAQ: CGEN ) on Monday said it had appointed Alberto Sessa as its CFO. The appointment follows the departure of previous CFO Ari Krashin in May. Sessa will join CGEN on Nov. 1, 2022, the company said. ...
Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer PR Newswire HOLON, Israel , Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target dis...
Compugen to Participate in Upcoming Fierce Biotech Summit PR Newswire YaronTurpaz, Ph.D., SVP and Senior Advisor, Computational Discovery, Compugen to participate in a panel discussion on leveraging artificial intelligence and machine learning to advance discovery and ...
Compugen ( NASDAQ: CGEN ) said that the Japan Patent Office granted a new composition of matter and use patent covering its anti-PVRIG, COM701 and backup anti-PVRIG antibodies. The Japanese patent No. 2017-562952 is expected to expire not before 2036. The...
Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan PR Newswire HOLON, Israel , Aug. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pion...
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio PR Newswire HOLON, Israel , Aug. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, an...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Viacheslav Lopatin / Shutterstock.com Just when we thought we were putting pandemics and public health crises behind us, “monkeypox” arises. Over the past few weeks, it’s raised eyebr...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...